Efficacy and Safety Study of SCT800 for On-demand Treatment With in Patients With Hemophilia A

Summary

In this trial safety and efficacy of SCT800 (B-domain deleted recombinant factor VIII) is being evaluated in 50 subjects, 12 to 65 years of age, with moderate to severe Hemophilia A. These subjects will receive open label treatment with SCT800 for approximately 6 months for on-demand treatment.

Timeline

Start

2016-10

Primary completion

2017-12

Completion

2018-06

Drugs

Indications